PRTK News and Press, Paratek Pharmaceuticals Inc. From 12/16/21

Calliditas Therapeutics (NASDAQ:CALT) +38% on FDA approval for kidney disease therapy. Kaixin Auto (NASDAQ:KXIN) +27% on a partnership agreement with Bujia for 10k new energy trucks. Biomerica (NASDAQ:BMRA) +18% preliminary second quarter revenue increase of approxima...

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that Evan Loh, chief executive officer, will present at the 2021 Jefferies London Healthcare Conference. The on-demand presentation will be available Thursday, Nov. 18 beginning at 3 a.m. ...

Paratek Pharmaceuticals, Inc. (PRTK) Q3 2021 Earnings Conference Call November 09, 2021, 04:30 PM ET Company Participants Evan Loh – CEO Sarah Higgins – Vice President Finance Controller Adam Woodrow – President and Chief Commercial Officer Randy Brenner – Chief De...

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) are up 6% in after-hours trading after the company's Q3 2021 earnings beat on both EPS and revenue. The company also said it anticipates full-year revenue of Nuzyra (omadacycline) will be at the higher end of the previously indicated r...

Paratek Pharmaceuticals (NASDAQ:PRTK): Q3 GAAP EPS of -$0.37 beats by $0.08. Revenue of $24.45M (+79.0% Y/Y) beats by $0.63M. Press Release Financial Guidance  Paratek anticipates net revenue of NUZYRA will be at the higher end of the previously indicated range of $100 to $106 million, w...

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.4 Million from the Core Commercial Business a lone , a 30% Increase over Prior Quarter -- BARDA Contract Expanded to Include sNDA Anthrax Post-Exposure Prophylaxis Development Program; Contract n ...

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, Nov. 8, 2021 at 4:30 p.m. EST to provide a corporate update and report its financial results for the third qu...

Today, we take a quick look back at antibiotic concern Paratek Pharmaceuticals. While I am very underweight the antibiotic space due to the terrible economics there, Paratek has some unique features that make the stock one I own. An analysis and how I am positioned in Paratek Phar...

BOSTON, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the first patient has been enrolled in the company’s Phase 2b study evaluating the safety and efficacy of NUZYRA ® (omadacycline) for the treatment for nontuberculous ...

Today, we revisit Spero Therapeutics for the first time in three years. The company is about to file its first NDA with the FDA by the end of the year. A full investment analysis follows in the paragraphs below. For further details see: Sizing Up Spero Therapeutics